Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 6/2005

01-12-2005 | Commentary

Cortactin overexpression results in sustained epidermal growth factor receptor signaling by preventing ligand-induced receptor degradation in human carcinoma cells

Authors: Agnes GSH van Rossum, Johan Gibcus, Jacqueline van der Wal, Ed Schuuring

Published in: Breast Cancer Research | Issue 6/2005

Login to get access

Abstract

The chromosome 11q13 region is frequently amplified in human carcinomas and results in an increased expression of various genes including cortactin, and is also associated with an increased invasive potential. Cortactin acts as an important regulator of the actin cytoskeleton. It is therefore very tempting to speculate that cortactin is the crucial gene within the 11q13 amplicon that mediates the invasive potential of these carcinomas. Cortactin also participates in receptor-mediated endocytosis, and recent findings have shown that, during receptor internalization, cortactin overexpression inhibits the ubiquitylation-mediated degradation of the epidermal growth factor receptor, resulting in a sustained ligand-induced epidermal growth factor receptor activity.
Literature
1.
van Rossum AG, Schuuring-Scholtes E, Buuren-van Seggelen V, Kluin PM, Schuuring E: Comparative genome analysis of cortactin and HS1: the significance of the F-actin binding repeat domain. BMC Genomics. 2005, 6: 15-CrossRefPubMedPubMedCentral
2.
Weed SA, Parsons JT: Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene. 2001, 20: 6418-6434.CrossRefPubMed
3.
4.
Huang C, Liu J, Haudenschild CC, Zhan X: The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells. J Biol Chem. 1998, 273: 25770-25776.CrossRefPubMed
5.
Li Y, Tondravi M, Liu J, Smith E, Haudenschild CC, Kaczmarek M, Zhan X: Cortactin potentiates bone metastasis of breast cancer cells. Cancer Res. 2001, 61: 6906-6911.PubMed
6.
van Rossum AG, De Graaf JH, Schuuring-Scholtes E, Kluin PM, Fan YX, Zhan X, Moolenaar WH, Schuuring E: Alternative splicing of the actin binding domain of human cortactin affects cell migration. J Biol Chem. 2003, 278: 45672-45679.CrossRefPubMed
7.
Bowden ET, Barth M, Thomas D, Glazer RI, Mueller SC: An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation. Oncogene. 1999, 18: 4440-4449.CrossRefPubMed
8.
Schuuring E, Verhoeven E, Mooi WJ, Michalides RJ: Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene. 1992, 7: 355-361.PubMed
9.
Schuuring E, Verhoeven E, Litvinov S, Michalides RJ: The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell–substratum contact sites. Mol Cell Biol. 1993, 13: 2891-2898.CrossRefPubMedPubMedCentral
10.
Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL: Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat. 2003, 78: 323-335.CrossRefPubMed
11.
Schuuring E: The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes – a review. Gene. 1995, 159: 83-96.CrossRefPubMed
12.
Schuuring E, Verhoeven E, van Tinteren H, Peterse JL, Nunnink B, Thunnissen FB, Devilee P, Cornelisse CJ, van de Vijver MJ, Mooi WJ: Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res. 1992, 52: 5229-5234.PubMed
13.
Lua BL, Low BC: Cortactin phosphorylation as a switch for actin cytoskeletal network and cell dynamics control. FEBS Lett. 2005, 579: 577-585.CrossRefPubMed
14.
Kaksonen M, Peng HB, Rauvala H: Association of cortactin with dynamic actin in lamellipodia and on endosomal vesicles. J Cell Sci. 2000, 113: 4421-4426.PubMed
15.
McNiven MA, Kim L, Krueger EW, Orth JD, Cao H, Wong TW: Regulated interactions between dynamin and the actin-binding protein cortactin modulate cell shape. J Cell Biol. 2000, 151: 187-198.CrossRefPubMedPubMedCentral
16.
Sauvonnet N, Dujeancourt A, Dautry-Varsat A: Cortactin and dynamin are required for the clathrin-independent endocytosis of γc cytokine receptor. J Cell Biol. 2005, 168: 155-163.CrossRefPubMedPubMedCentral
17.
Zhu J, Zhou K, Hao JJ, Liu J, Smith N, Zhan X: Regulation of cortactin/dynamin interaction by actin polymerization during the fission of clathrin-coated pits. J Cell Sci. 2005, 118: 807-817.CrossRefPubMed
18.
Merrifield CJ, Perrais D, Zenisek D: Coupling between clathrin-coated-pit invagination, cortactin recruitment, and membrane scission observed in live cells. Cell. 2005, 121: 593-606.CrossRefPubMed
19.
Le Roy C, Wrana JL: Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol. 2005, 6: 112-126.CrossRefPubMed
20.
Marmor MD, Yarden Y: Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene. 2004, 23: 2057-2070.CrossRefPubMed
21.
Timpson P, Lynch DK, Schramek D, Walker F, Daly RJ: Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor. Cancer Res. 2005, 65: 3273-3280.PubMed
22.
Wu WJ, Tu S, Cerione RA: Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation. Cell. 2003, 114: 715-725.CrossRefPubMed
23.
Hou P, Estrada L, Kinley AW, Parsons JT, Vojtek AB, Gorski JL: Fgd1, the Cdc42 GEF responsible for Faciogenital Dysplasia, directly interacts with cortactin and mAbp1 to modulate cell shape. Hum Mol Genet. 2003, 12: 1981-1993.CrossRefPubMed
24.
Bao J, Gur G, Yarden Y: Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors. Proc Natl Acad Sci USA. 2003, 100: 2438-2443.CrossRefPubMedPubMedCentral
25.
Nadal A, Cardesa A: Molecular biology of laryngeal squamous cell carcinoma. Virchows Archiv. 2003, 442: 1-7.PubMed
Metadata
Title
Cortactin overexpression results in sustained epidermal growth factor receptor signaling by preventing ligand-induced receptor degradation in human carcinoma cells
Authors
Agnes GSH van Rossum
Johan Gibcus
Jacqueline van der Wal
Ed Schuuring
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1316

Other articles of this Issue 6/2005

Breast Cancer Research 6/2005 Go to the issue

Review

Overdiagnosis and overtreatment of breast cancer: Overdiagnosis and overtreatment in service screening

Research article

Allelic imbalances of chromosomes 8p and 18q and their roles in distant relapse of early stage, node-negative breast cancer

Viewpoint

What does an orphan G-protein-coupled receptor have to do with estrogen?

Commentary

Clinical trial update: International Breast Cancer Study Group

Research article

Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells

Commentary

CYP17 and breast cancer: no overall effect, but what about interactions?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits